Empagliflozin/Metformin Hydrochloride

恩格列净/盐酸二甲双胍

Report date: 2026/03/23 20:03:44

Base Information

Drug NameEmpagliflozin/Metformin Hydrochloride
Drug Alias Name盐酸二甲双胍/恩格列净Empagliflozin/Metformin恩格列净二甲双胍Metformin Hydrochloride and EmpagliflozinEmpagliflozin and Metformin Hydrochloride +[10] 
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsHyperglycemiaDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2015/05/27
Country/TerritoryCzechiaCanadaUnited States +[25] 
CombinationsYes Metformin HydrochlorideEmpagliflozin
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim Pty LtdC.H. Boehringer Sohn Ag & Co. KgHumanis Saglık Anonim Sirketi +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsHyperglycemia

Other Information

ATC CodeA10BD20
Related LinksWikipediaKEGG